Objective: Prognostic predictors for newly diagnosed malignant lymphoma are well known. However, they have not been compared for patients with recurrent or refractory malignant lymphoma. Methods: We retrospectively analyzed biological prognostic predictors for patients with recurrent or refractory aggressive lymphoma, such as serum levels of C-reactive protein, lactate dehydrogenase, hemoglobin, b2-microglobulin and soluble interleukin-2 receptor before salvage therapy. The primary endpoint was overall survival after salvage treatment. First, univariate and multivariate analyses were performed for each of the parameters, using the logrank test and Cox regression analysis, respectively. Secondly, we classified the patients into three risk groups on the basis of significant poor predictors. Results: Sixty-three patients, including 41 patients with diffuse large B-cell lymphoma, were included in this study. Overall survival was significantly worse in patients with elevated C-reactive protein level (hazard ratio 3.757; P ¼ 0.017), elevated lactate dehydrogenase level (hazard ratio 3.948; P ¼ 0.010) and anemia (hazard ratio 3.925; P ¼ 0.016) by multivariate analysis. We classified patients into two groups based on these three biological parameters. The median overall survival of the high-and low-risk patients was 5.8 and 60.1 months, respectively (log-rank test; P , 0.001). The overall response rate was significantly higher among the low-risk patients than among the high-risk patients (71.4 versus 28.6%, P ¼ 0.005). Those results were similar among all aggressive lymphoma and diffuse large B-cell lymphoma. Conclusions: Elevated C-reactive protein level, elevated lactate dehydrogenase level and anemia before salvage treatment predicted poorer outcomes among patients with recurrent or refractory aggressive lymphoma.
INTRODUCTION
For patients who have experienced recurrence or are refractory to induction therapy, we have the choice of salvage chemotherapies such as ICE (1) , DHAP (2) , ESHAP (3) and so on. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the treatment of choice for patients with recurrent or relapsed aggressive lymphoma who still respond to salvage therapy (4, 5) . Recently, the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study published a study comparing the effects of two well-established salvage regimens, R-ICE and R-DHAP, followed by autologous hematopoietic stem cell transplantation for relapsed and large B-cell lymphoma in the Rituximab era (6) .
Prognostic predictors for newly diagnosed malignant lymphoma, such as the International Prognostic Index (IPI) (7) , Revised IPI (R-IPI) (8) , Follicular Lymphoma IPI (FLIPI) (9) , Prognostic Index for Peripheral T-cell Lymphoma (PIT) (10) and International Prognostic Score (IPS) (11) , are well known. Moreover, several prognostic factors for the outcome of autologous hematopoietic stem cell transplantation have been described in the literature: chemotherapy sensitivity before autologous hematopoietic stem cell transplantation (12) , time from diagnosis to relapse of ,12 months (13) and the presence of prognostic factors at relapse, as defined by the Secondary Age-Adjusted IPI (saaIPI) (14, 15) . On the other hand, prognostic factors have not been compared for patients who are eligible and ineligible for autologous hematopoietic stem cell transplantation, with recurrent or refractory malignant lymphoma.
The purpose of this study was to investigate laboratory prognostic factors, including serum C-reactive protein (CRP) level, serum lactate dehydrogenase (LDH) level, hemoglobin concentration (Hb), serum b2-microglobulin (b2M) level and serum soluble interleukin-2 receptor (sIL-2R) level before salvage therapy, in order to evaluate them for overall survival (OS) among patients with recurrent or relapsed aggressive lymphoma treated with ICE or DHAP with or without rituximab. All of the patients were enrolled in a retrospective single-center study at the Cancer Institute Hospital, Japanese Foundation for Cancer Research.
METHODS

PATIENTS
We retrospectively analyzed patients with recurrent or refractory malignant lymphoma treated with ICE or DHAP with or without rituximab as salvage treatment in our institute from April 2005 to June 2010. All the patients received ICE and DHAP as the first salvage therapy. Patients were analyzed if they were older than 18 years with aggressive lymphoma. Patients were excluded if they had clinically relevant cardiac disease or positivity for antibodies against HIV-1 or -2. We define recurrent and refractory disease by Cheson's criteria in 1999 (16) . They included the following subtypes: 41 diffuse large B-cell lymphoma, 8 peripheral T-cell lymphoma not otherwise specified, 6 angioimmunoblastic T-cell lymphoma, 4 extranodal NK/T lymphoma, nasal-type, 2 anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma and 2 follicular lymphoma, grade 3b. Two patients was transformed B-cell lymphoma from follicular lymphoma, and extranodal marzinal zone lymphoma of mucosa-associated lymphoid tissue. All pathological specimens were diagnosed by hematopathologists in our institute. This study was approved by the Independent Ethics Committees/Institutional Review Boards in our institute. Patients provided written informed consent before entering the study, which was carried out in accordance with the Declaration of Helsinki.
TREATMENT AND Evaluations were carried out on the following criteria. Complete remission was defined as the disappearance of all clinical evidence of lymphoma, with no persisting diseaserelated symptoms. Partial response was defined as a decrease .50% in the sum of the products of the two longest diameters of all measurable lesions and non-measurable lesions had to decrease by at least 50%. Progressive disease was defined as any increase .50% in the sum of the diameters of any measurable lesions or the appearance of new lesions. Stable disease was considered to be any condition intermediate between partial response and progressive disease (16) .
PROGNOSTIC FACTORS
The following parameters were recorded and evaluated for prognosis: serum CRP level, serum LDH level, Hb, serum b2M level and serum sIL-2R level before salvage therapy. The cut-offs of CRP, LDH and b2M levels were defined with upper normal limits, and that of Hb was defined with a lower normal limit. The cut-off of sIL-2R was defined as 1000 IU/l. Moreover, we analyzed other, well-established prognostic factors: age .60 years, stage of the disease beyond II, performance status .1, IPI .2 and interval from induction therapy to salvage therapy within 1 year. The disease stage was determined according to the Ann Arbor classification, and the performance status was determined
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CRP, LDH and anemia for lymphoma according to the Eastern Cooperative Oncology Group (ECOG) score.
STATISTICAL ANALYSIS
The primary endpoint was to evaluate laboratory parameters that would predict poor OS after salvage treatments were started. First, univariate analysis was performed for each of the parameters indicated above. Actuarial survival analysis was performed by the method described by Kaplan and Meier, and the curves were compared by the log-rank test. All prognostic variables were considered for the multivariate analysis for survival. The latter was performed by Cox regression analysis. Secondly, we classified the patients into three risk groups due to significant poor predictors from the laboratory parameters. Actuarial survival analysis among the two risk groups was performed by the method described by Kaplan and Meier, and the curves were compared by log-rank test. Moreover, we analyzed prognostic factors between significant poor predictors from the laboratory parameters and well-established prognostic factors, such as disease status, performance status, international index and interval from induction therapy to salvage therapy, by Cox regression analysis. Secondly, correlations between partial response plus complete remission rate by salvage therapies and the laboratory parameters were assessed by the x 2 test and Fisher's exact test. Finally, we analyzed the correlation between the five laboratory parameters by Pearson's product -moment correlation coefficient in order to know whether the significant risk factors predicted poor outcome independently. All P-values reported were two-sided, and statistical significance was defined as P , 0.05. The statistical analyses were performed with the SPSS statistical software (SPSS, Inc., Chicago, IL, USA).
RESULTS
PATIENTS AND TREATMENT
Sixty-three patients with recurrent or refractory malignant lymphoma were enrolled into this study; of which, 46 had recurrent lymphoma and 17 had refractory lymphoma. The main patient characteristics are shown in Table 1 . The median age of the patients in this study was 59.5 years (range, 26.9 -76.1 years). As induction therapy, 39 received R-CHOP, 16 had CHOP, 3 had EPOCH, 2 had DeVIC plus radiation therapy, 1 had high-CHOP, 1 had radiation therapy and 1 was unknown. The levels of laboratory factors are shown in Table 2 . The median levels of CRP, LDH, Hb, b2M and sIL-2R were 0.3 IU/l (range, 0.1 -26.7 IU/l), 258 IU/l (range, 130 -6510 IU/l), 11.8 g/l (5.0 -15.8 g/l), 2.08 IU/l (range, 1.21 -4.44 IU/l) and 984 IU/l (range, 296 -7840 IU/l), respectively. Fifty and 13 patients received ICE and DHAP as a salvage therapy, respectively. The median number of cycles of ICE and DHAP were three (range, 1 -4) and two (range, 1 -3), respectively. The median OS of high-and low-risk patients was 5.8 months (95% CI 3.3 -8.3) and 60.1 months (95% CI 0.0 -125.0), respectively. There was a significant difference among high-and low-risk patients in all patients (log-rank test; P , 0.001, Fig. 1 ). Moreover, among the patients with 39 diffuse large B-cell lymphoma patients, excluding two transformed large B-cell lymphoma, the median OS of highand low-risk patients was 9.5 months (95% CI 1.3 -17.7) and 60.1 months (95% CI 0.0 -121.0), respectively. There was a significant difference among high-and low-risk patients for patients with diffuse large B-cell lymphoma (log-rank test; P ¼ 0.014, Fig. 2 ). Figure 1 . The LAC index among all patients. The median overall survival of high-and low-risk patients were 5.8 months (95% CI 3.3 -8.3) and 60.1 months (95% CI 0.0-125.0), respectively. There was a significant difference among high-and low-risk patients in all patients (log-rank test; P , 0.001).
CRP, LDH and anemia for lymphoma
We evaluated the LAC index among patients treated with ICE and DHAP separately. Among the patients treated with ICE, the median OS of high-and low-risk patients was 9.5 months (95% CI 0 -21.3) and 63.2 months (95% CI 0.0 -140.9), respectively. Among the patients treated with DHAP, the median OS of high-and low-risk patients was 4.7 months (95% CI 3.7 -5.8) and 13.8 months (95% CI 13.5 -14.2), respectively. There was a significant difference in OS among high-and low-risk patients for patients who were treated with ICE and DHAP (log-rank test; P ¼ 0.004 and 0.006, respectively).
Among the patients with all lymphoma, the overall response rate was significantly higher among the low-risk patients than that among the high-risk patients (71.4 versus 28.6%, P ¼ 0.005). The complete remission rate was significantly higher among the low-risk patients than that among the high-risk patients (45.2 versus 9.5%, P ¼ 0.030). Moreover, among the patients with diffuse large B-cell lymphoma, the overall response rate was significantly higher among the low-risk patients than that among the high-risk patients (81.8 versus 21.4%, P ¼ 0.001). The complete remission rate was significantly higher among the low-risk patients than that among the high-risk patients (45.5 versus 7.1%, P ¼ 0.025).
Our analysis comparing the LAC index score with wellestablished factors is shown in We applied the R-IPI and IPI in our patients. We evaluated the outcome classified by the R-IPI among 29 patients treated with rituximab plus salvage chemotherapy. According to the R-IPI in our patients, the median OS rates of the high-risk, intermediate-risk and low-risk groups were 12.3 months (95% CI 7.5 -17.1), not reached, and not reached, respectively. There was a significant difference among the three risk groups (log-rank test; P ¼ 0.040, Fig. 3) . We evaluated the outcome classified by the IPI among our patients without angioimmunoblastic T-cell lymphoma. According to the IPI in our patients, the median OS rates of high-risk, high-intermediate-risk, low-intermediate-risk and low-risk groups were 12.9 months (95% CI 2.7-23.0), 9.5 months (95% CI 3.0 -16.0), not reached, and not reached, respectively. There was not a significant difference among the four risk groups (log-rank test; P ¼ 0.106, Fig. 4 ).
CORRELATIONS BETWEEN FIVE PROGNOSTIC FACTORS IN OUR MODEL
According to Pearson's product -moment correlation coefficient, the closer to 1.00 the r value, the stronger correlations become. First, we analyzed the correlation between five laboratory parameters before salvage therapy. There is moderate correlation between CRP and Hb, sIL-2R and Hb, sIL-2R and b2M (correlation coefficient, r ¼ 0.362, 0.334, and 0.301, respectively). On the other hand, there is little correlation between LDH and Hb, and LDH and CRP (correlation coefficient, r ¼ 0.252, and 0.64, respectively). Secondly, we analyzed the correlation between parameters before salvage therapy and before induction therapy. There is moderate correlation between b2M and sIL-2R before salvage therapy and before induction therapy (correlation coefficient, r ¼ 
DISCUSSION
This study suggested that OS after salvage treatment, ICE or DHAP, had started significantly worsened in patients with elevated CRP, elevated LDH and anemia for aggressive malignant lymphoma. Several well-known prognostic predictors for newly diagnosed malignant lymphoma, such as IPI, R-IPI, FLIPI, PIT and IPS, included elevated CRP level, elevated LDH level and anemia (7 -11) . CRP is a member of the class of acute-phase reactants, as its level rises dramatically during inflammatory processes occurring in the body. Elevation of serum CRP is due to a rise in the plasma concentration of interleukin-6, which is produced predominantly by macrophages as well as adipocytes. Interleukin-6 is a potent lymphoid growth and differentiation cytokine produced by various types of cells, including benign and malignant B and T lymphocytes. Interleukin-6 is implicated in the pathogenesis of several lymphoproliferative disorders, which has been reported as an independent prognostic factor for complete remission and failure-free survival among diffuse large cell lymphomas (17, 18) . CRP has been reported to be strongly correlated with the Ann Arbor clinical stages (19) .
Serum LDH represents a surrogate quantitative measure for tumor burden. A high serum LDH level is correlated with the progression of disease in non-Hodgkin's lymphoma (20, 21) . Combined with serum LDH and b2M provides a reliable serologic system for predicting freedom from relapse and survival in large cell lymphoma. Moreover, elevations in both serum LDH and b2M levels predict shortened remission and survival (22) .
Anemia is important as a prognostic factor in malignant lymphomas. Its presence is correlated with well-known prognostic factors related to patient and tumor (23) . The pathogenesis of anemia in lymphoma is unclear. However, several mechanisms must be considered, such as auto-immune hemolysis, bone marrow involvement and the effects of inflammatory cytokines. Anemia in chronic disease is characterized by bone marrow erythroid hypoplasia, a shortened survival of erythrocytes, and deficient erythropoietin production for the hemoglobin level (24, 25) . Among patients with lymphomas, anemia may be associated with high inflammatory cytokine production by lymphoma or reactive cells. The inflammatory cytokines, such as interleukin (IL)-1, -6, -10 and tumor necrosis factor-a (TNF-a), reduce erythropoietin production and inhibit the response of erythroid progenitors to erythropoietin in vitro (26 -29) . Elevated TNF-a level is associated with anemia among lymphoma patients (30) . On the other hand, hepcidin, an iron-regulated acute-phase protein that is composed of 25 amino acids, has helped to shed light on the relationship of the immune response to iron homeostasis and anemia of chronic disease. Hepcidin expression is induced by lipopolysaccharide and IL-6 (31).
A high serum b2M level is known to be an adverse prognostic factor in lymphoproliferative diseases, being directly related to malignant tumor burden (32), but it also keeps its Figure 3 . The R-IPI in our patients. According to the R-IPI in our patients, the median overall survival rates of the high-, intermediate-and low-risk groups were 12.3 months (95% CI 7.5 -17.1), not reached, and not reached, respectively. There was a significant difference between three risk groups (log-rank test; P ¼ 0.040). The IPI in our patients. According to the IPI in our patients, the median overall survival rates of high-risk, high-intermediate-risk, low-intermediate-risk and low-risk groups were 12.9 months (95% CI 2.7 -23.0), 9.5 months (95% CI 3.0 -16.0), not reached, and not reached, respectively. There was not a significant difference among four risk groups (log-rank test; P ¼ 0.106).
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CRP, LDH and anemia for lymphoma adverse prognostic role when other causes, such as renal dysfunction, are the origin of the raised levels. The b2M level is an independent prognostic value in aggressive nonHodgkin's lymphomas (22, (33) (34) (35) . A high level of sIL-2R before treatment is associated with tumor burden and poor prognosis among lymphoma patients (36 -38) . IL-2R is expressed on the cell membrane of lymphocytes and plays important roles in their activation and proliferation (39) . A high serum sIL-2R level reflects elevated activity of T cells in the patient's cellular immunity. The serum sIL-2R level reflects the prognosis more obviously in patients with T-cell lymphoma than with B-cell lymphoma because both activated T-and lymphoma cells produce sIL-2R in T-cell lymphoma (40) .
We demonstrated that an elevated CRP level, elevated LDH level and anemia were independent prognostic factors for OS among patients with recurrent or refractory aggressive malignant lymphoma. On the other hand, some inflammatory cytokines, such as IL-6 and TNF-a, are related with both anemia and CRP. In our analysis, there is no significant relationship between anemia and CRP because of the result of the correlation between anemia and CRP by Pearson's product -moment correlation coefficient (P ¼ 0.139).
We analyzed prognostic factors between the LAC index and well-established prognostic factors such as disease status, interval from induction therapy to salvage treatment (11), international prognostic factor (14, 15) and performance status. The LAC index was one of the independent and significant prognostic factors for OS. Moreover, the overall response rate and complete remission rate were significantly higher in the low-risk patients than that in the high-risk patients. The results of OS, overall response and complete remission rates were similar among the patients with both all aggressive lymphoma and diffuse large B-cell lymphoma. The result demonstrates that ICE or DHAP is very effective among the low-risk patients, and new strategies are necessary for the high-risk patients.
Finally, we applied the R-IPI at relapse and IPI at relapse in our patients. There was no significant difference in OS by the R-IPI at relapse and the IPI at relapse in our patients. This may have been due to the small number of patients in our model and the short follow-up time. However, we demonstrate that elevated CRP level, elevated LDH level, anemia and LAC index were strong predictors of poor outcome.
In conclusion, an elevated CRP level, elevated LDH level and anemia were predictive factors for poorer outcomes among patients with recurrent or refractory aggressive lymphoma treated with ICE or DHAP. We classified patients into two groups based on these three predictors, and there was a significant difference in OS among high-and low-risk patients with both all aggressive lymphomas and diffuse large B-cell lymphoma. High-risk by the LAC index was an independent prognostic factor for OS for patients with recurrent or relapsed aggressive lymphoma. However, our sample size is small, and larger scale research would increase our understanding of how best to treat these patients.
